Economic evaluation of pan-genotypic generic direct-acting antiviral regimens for treatment of chronic hepatitis C in Iran: a cost-effectiveness study

INTRODUCTION: Low-cost generic direct-acting antiviral (DAA) regimens for treatment of hepatitis C virus (HCV) are available in several low-income/middle-income countries, important for treatment scale-up. This study evaluated the cost-effectiveness of genotype-dependent and pan-genotypic DAA regime...

Descripción completa

Detalles Bibliográficos
Autores principales: Tasavon Gholamhoseini, Mohammad, Sharafi, Heidar, HL Borba, Helena, Alavian, Seyed Moayed, Sabermahani, Asma, Hajarizadeh, Behzad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Health Economics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9185662/
https://www.ncbi.nlm.nih.gov/pubmed/35676019
http://dx.doi.org/10.1136/bmjopen-2021-058757

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9185662/
https://www.ncbi.nlm.nih.gov/pubmed/35676019
http://dx.doi.org/10.1136/bmjopen-2021-058757

Ejemplares similares